Search results for: "Novo Nordisk"

(167 records)

Regulatory
Generic drugs to face 100% and 200% tariffs after 2028, says Trump

Generic drugs to face 100% and 200% tariffs after 2028, says Trump

The President said all generic drugs coming into the US will have a tariff rate of 100% after 2028, rising to 200% in 2029 in an effort to reshore drugmaking into America
Media
Novo Nordisk sues Eli Lilly over Wegovy vs Zepbound ad claims

Novo Nordisk sues Eli Lilly over Wegovy vs Zepbound ad claims

Novo Nordisk has filed a US lawsuit accusing Eli Lilly of false advertising, alleging Zepbound campaigns omit newer high-dose Wegovy data
Research & Development
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline...
Regulatory
MHRA approves first oral semaglutide tablet for weight loss in the UK

MHRA approves first oral semaglutide tablet for weight loss in the UK

Novo Nordisk's Wegovy tablet becomes the UK's first GLP-1 receptor agonist in oral form for obesity treatment — a significant shift in delivery format as the drug awaits NICE...
Finance
Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings

Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings

The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected...
Pharma 5.0
Novo Nordisk and OpenAI partner to accelerate drug discovery with AI integration

Novo Nordisk and OpenAI partner to accelerate drug discovery with AI integration

The Wegovy and Ozempic maker has struck a strategic deal with OpenAI to embed artificial intelligence across its entire operations, with full integration targeted by the end of...
Regulatory
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or...
You need to be a subscriber to read this article.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a...
Pharmaceutical
Novo Nordisk and Hims end GLP-1 spat, strike deal to sell Wegovy and Ozempic

Novo Nordisk and Hims end GLP-1 spat, strike deal to sell Wegovy and Ozempic

The pair have reached an agreement under which the telehealth company can sell Novo's Ozempic and Wegovy, ending a legal dispute that flared last month
Manufacturing
Novo Nordisk plans Ireland expansion to manufacture oral Wegovy for global markets

Novo Nordisk plans Ireland expansion to manufacture oral Wegovy for global markets

The company is preparing to scale production capacity at its Athlone facility as strong US uptake of its oral obesity therapy supports a broader strategy to expand global...
Regulatory
Hims & Hers backs down on oral GLP-1 copycat after FDA pressure

Hims & Hers backs down on oral GLP-1 copycat after FDA pressure

Facing threats of legal action from Wegovy manufacturer Novo Nordisk and an FDA probe, the health and wellness company has decided to abandon its plans to offer a GLP-1 copycat
Drug Delivery
Indonesia looks to oral GLP-1s as it battles rising obesity

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction...
Finance
Global consortium launches to accelerate antibiotic discovery

Global consortium launches to accelerate antibiotic discovery

The $60m consortium backed by the Gates Foundation, Novo Nordisk Foundation and Wellcome aims to speed the discovery of next-generation antibiotics to tackle the growing threat...
Finance
Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation

Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation

The long-term funding will enable the BioInnovation Institute to expand into new scientific fields and European markets, strengthening translation of academic research into...
Pharmaceutical
Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill

Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill

The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
Regulatory
Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court

Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court

The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign...

Trending Articles

  1. Loftware and RiseNow partner to strengthen supply chain traceability and compliance in healthcare settings The alliance pairs Loftware's SAP-integrated product identification platform with RiseNow's procurement and supply chain advisory services, delivering end-to-end track-and-trace capabilities for regulated industries where audit readiness and patient safety are critical
  2. Hanmi licenses UCN2 obesity drug candidate HM17321 to Genentech in $2.3bn deal Hanmi Pharm has granted Genentech global rights to develop and commercialise HM17321, an investigational UCN2 analogue designed to drive weight loss while preserving lean mass
  3. CEPI announces $4.17m for studies assessing existing Ebola vaccines against Bundibugyo strain Four CEPI-backed research projects will analyse thousands of stored blood samples to determine whether vaccines against Zaire ebolavirus, including Ervebo, generate immune responses to Bundibugyo ebolavirus
  4. FairJourney Bio engineers tumour-conditional IL-12 switch to improve therapeutic window The company has engineered a dual-specificity antibody fragment designed to activate IL-12 selectively in the tumour microenvironment, with preclinical data and quantitative systems pharmacology modelling indicating potential for reduced systemic toxicity
  5. AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming global rights to ACD856 and the NeuroRestore platform

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Research & Development AKIR001 is a targeted antibody-radionuclide conjugate designed to deliver radiation directly to CD44v6-expressing solid tumours, with potential to become a first-in-class therapy
Akiram and ITM sign supply agreement to develop AKIR001 to treat solid tumours

Akiram and ITM sign supply agreement to develop AKIR001 to treat solid tumours

Read more
Research & Development Lupin has recently announced two significant developments, reinforcing its momentum in both the US generics market and its global speciality care strategy
Lupin advances speciality pipeline with FDA approval and European partnership

Lupin advances speciality pipeline with FDA approval and European partnership

Read more
Research & Development Jocasta Neuroscience has secured expanded exclusive rights to UCSF α-klotho intellectual property as it advances JN-0413 towards first-in-human testing for cognitive...
Jocasta expands UCSF α-klotho licence ahead of 2027 Phase I trial

Jocasta expands UCSF α-klotho licence ahead of 2027 Phase I trial

Read more
Manufacturing Alcami combines deep analytical expertise, flexible manufacturing, and advanced packaging capabilities to deliver a more seamless pathway from development to commercial supply
Strengthening end-to-end capabilities for modern drug development

Strengthening end-to-end capabilities for modern drug development

Read more
Packaging OPTIMA has published its second CSRD-aligned sustainability report, highlighting progress on renewable energy, emissions management, energy-efficient machinery and information...
OPTIMA expands sustainability drive across machinery portfolio

OPTIMA expands sustainability drive across machinery portfolio

Read more
Packaging Artificial intelligence is rapidly transitioning from a technology pipedream to an operational reality for many businesses in the pharmaceutical and medical device...
Why poor data quality has the potential to derail AI in pharma

Why poor data quality has the potential to derail AI in pharma

Read more
Analysis The launch comes as base editing advances toward the clinic and regulators place greater emphasis on sensitive, orthogonal approaches to genome safety
MaxCyte launches CHANGE-seq-BE and ONE-seq-BE to strengthen off-target assessment for genome editing therapies

MaxCyte launches CHANGE-seq-BE and ONE-seq-BE to strengthen off-target assessment for genome editing therapies

Read more
Sustainability Bespak, the specialist inhalation CDMO, has achieved a Gold EcoVadis sustainability rating for its Holmes Chapel site. The result places Bespak among the top 5% of companies...
Bespak awarded gold EcoVadis sustainability rating for its Holmes Chapel (UK) site

Bespak awarded gold EcoVadis sustainability rating for its Holmes Chapel (UK) site

Read more